Quadrature Capital’s Nurix Therapeutics NRIX Stock Holding History

Quadrature Capital’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,172	Closed	-$193K	–	1707
2025 Q4	$193K	Buy	+10,172	New	+$146K	﹤0.01%	982

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Quadrature Capital's NRIX Position: Q1 2026 in Review

Quadrature Capital sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 10,172 shares — an estimated $193K sold.

Quadrature Capital first reported a position in NRIX in Q4 2025 and held it in 1 quarter. The position peaked at $193K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Quadrature Capital reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
Quadrature Capital sold 10,172 Nurix Therapeutics shares in Q1 2026, an estimated $193K.
Quadrature Capital first reported a position in Nurix Therapeutics in Q4 2025 and held it in 1 quarter.
Quadrature Capital's Nurix Therapeutics position peaked at $193K in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.